Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU Amyloid Removal Trial (ART) – Lecanemab in Dominantly Inherited Alzheimer’s Disease
2024-513458-31-00Phase 4Completed
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of lecanemab in Alzheimer's disease (AD), sponsored by Washington University School of Medicine. Primary endpoints: Change from ART baseline to year 1 in amyloid PiB PET SUVR, Change from ART baseline to year 2 in amyloid PiB PET SUVR and 1 more. Started Oct 2024; status: completed.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-513458-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513458-31-00.